After years of witnessing a steady decline in generic drug manufacturing facility registrations with the US Food and Drug Administration (FDA), it seems that in 2021 the numbers will once again witness an increase, albeit marginally.
PharmaCompass analyzed the FDA database of facilities that have paid the user fee under the Generic Drug User Fee Act (GDUFA)....[PharmaCompass]
